MicroRNA‑944 targets vascular endothelial growth factor to inhibit cell proliferation and invasion in osteosarcoma

The aim of our study was to examine the involvement of renin-angiotensin system (RAS) in estrogen-induced lactotropes proliferation and vascular endothelial growth factor (VEGF) expression in rat pituitary. The study was performed on Fisher 344 rats underwent 8-day treatment with diethylstilboestrol (DES). The proliferation index (PCNA) and VEGF expression in pituitary sections were estimated using immunohistochemical methods. Treatment with DES increased the number of PCNA-positive cells, VEGF-positive cells, and VEGF-positive blood vessels in pituitary. Stimulatory effect of estrogen on cell proliferation and VEGF expression in blood vessels was attenuated by losartan, PD123319, and captopril. VEGF immunoreactivity in pituitary cells of DES-treated rats was decreased by AT1 antagonist and not changed by AT2 blocker and ACE inhibitor. Our findings suggest the involvement of RAS in DES-induced cell proliferation and VEGF expression in pituitary. Both the AT1 and AT2 receptors appear to mediate the estrogen-dependent mitogenic and proangiogenic effects in rat pituitary.

Download Full-text

Effect of Vascular Endothelial Growth Factor and Its Receptor Inhibitor on Proliferation and Invasion in Bladder Cancer

Urologia Internationalis ◽

10.1159/000224877 ◽

2009 ◽

Vol 83 (1) ◽

pp. 98-106 ◽

Cited By ~ 29

Author(s):

Ryoichi Nakanishi ◽

Natsuo Oka ◽

Hiroyoshi Nakatsuji ◽

Takahiro Koizumi ◽

Manabu Sakaki ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Bladder Cancer ◽

Growth Factor ◽

Vascular Endothelial ◽

Endothelial Growth Factor ◽

Proliferation And Invasion ◽

Receptor Inhibitor

Download Full-text

Successful inhibition of intracranial human glioblastoma multiforme xenograft growth via systemic adenoviral delivery of soluble endostatin and soluble vascular endothelial growth factor receptor-2

Journal of Neurosurgery ◽

10.3171/jns/2008/108/5/0979 ◽

2008 ◽

Vol 108 (5) ◽

pp. 979-988 ◽

Cited By ~ 20

Author(s):

Oszkar Szentirmai ◽

Cheryl H. Baker ◽

Szofia S. Bullain ◽

Ning Lin ◽

Masaya Takahashi ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Cell Proliferation ◽

Growth Factor ◽

Glioblastoma Multiforme ◽

Tumor Growth ◽

Growth Inhibition ◽

Growth Factor Receptor ◽

Vascular Endothelial ◽

Treatment Groups ◽

Endothelial Growth Factor

Object Glioblastoma multiforme (GBM) is characterized by neovascularization, raising the question of whether angiogenic blockade may be a useful therapeutic strategy for this disease. It has been suggested, however, that, to be useful, angiogenic blockade must be persistent and at levels sufficient to overcome proangiogenic signals from tumor cells. In this report, the authors tested the hypothesis that sustained high concentrations of 2 different antiangiogenic proteins, delivered using a systemic gene therapy strategy, could inhibit the growth of established intracranial U87 human GBM xenografts in nude mice. Methods Mice harboring established U87 intracranial tumors received intravenous injections of adenoviral vectors encoding either the extracellular domain of vascular endothelial growth factor receptor-2-Fc fusion protein (Ad-VEGFR2-Fc) alone, soluble endostatin (Ad-ES) alone, a combination of Ad-VEGFR2-Fc and Ad-ES, or immunoglobulin 1-Fc (Ad-Fc) as a control. Results Three weeks after treatment, magnetic resonance imaging-based determination of tumor volume showed that treatment with Ad-VEGFR2-Fc, Ad-ES, or Ad-VEGFR2-Fc in combination with Ad-ES, produced 69, 59, and 74% growth inhibition, respectively. Bioluminescent monitoring of tumor growth revealed growth inhibition in the same treatment groups to be 62, 74, and 72%, respectively. Staining with proliferating cell nuclear antigen and with terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling showed reduced tumor cell proliferation and increased apoptosis in all antiangiogenic treatment groups. Conclusions These results suggest that systemic delivery and sustained production of endostatin and soluble VEGFR2 can slow intracranial glial tumor growth by both reducing cell proliferation and increasing tumor apoptosis. This work adds further support to the concept of using antiangiogenesis therapy for intracranial GBM.

Download Full-text

Uniaxial cyclic strain stimulates cell proliferation and secretion of interleukin-6 and vascular endothelial growth factor of human dermal fibroblasts seeded on chitosan scaffolds

Journal of Biomedical Materials Research Part A ◽

10.1002/jbm.a.34881 ◽

2013 ◽

Vol 102 (7) ◽

pp. 2268-2276 ◽

Cited By ~ 13

Author(s):

Ki-Sook Park ◽

Eun-Gyu Lee ◽

Youngsook Son

Keyword(s):

Vascular Endothelial Growth Factor ◽

Cell Proliferation ◽

Growth Factor ◽

Interleukin 6 ◽

Cyclic Strain ◽

Dermal Fibroblasts ◽

Vascular Endothelial ◽

Human Dermal Fibroblasts ◽

Chitosan Scaffolds ◽

Endothelial Growth Factor

Download Full-text

Estrogen-Induced CCN1 Is Critical for Establishment of Endometriosis-Like Lesions in Mice

Molecular Endocrinology ◽

10.1210/me.2014-1080 ◽

2014 ◽

Vol 28 (12) ◽

pp. 1934-1947 ◽

Cited By ~ 8

Author(s):

Yuechao Zhao ◽

Quanxi Li ◽

Benita S. Katzenellenbogen ◽

Lester F. Lau ◽

Robert N. Taylor ◽

...

Keyword(s):

Vascular Endothelial Growth Factor ◽

Cell Proliferation ◽

Growth Factor ◽

Molecular Mechanisms ◽

Tissue Growth ◽

Endometrial Tissue ◽

Vascular Endothelial ◽

Wild Type ◽

Factor C ◽

Endothelial Growth Factor

Endometriosis is a prevalent gynecological disorder in which endometrial tissue proliferates in extrauterine sites, such as the peritoneal cavity, eventually giving rise to painful, invasive lesions. Dysregulated estradiol (E) signaling has been implicated in this condition. However, the molecular mechanisms that operate downstream of E in the ectopic endometrial tissue are unknown. To investigate these mechanisms, we used a mouse model of endometriosis. Endometrial tissue from donor mice was surgically transplanted on the peritoneal surface of immunocompetent syngeneic recipient mice, leading to the establishment of cystic endometriosis-like lesions. Our studies revealed that treatment with E led to an approximately 3-fold increase in the lesion size within a week of transplantation. E also caused a concomitant stimulation in the expression of connective tissue growth factor/Cyr61/Nov (CCN1), a secreted cysteine-rich matricellular protein, in the lesions. Interestingly, CCN1 is highly expressed in human ectopic endometriotic lesions. To address its role in endometriosis, endometrial tissue from Ccn1-null donor mice was transplanted in wild-type recipient mice. The resulting ectopic lesions were reduced up to 75% in size compared with wild-type lesions due to diminished cell proliferation and cyst formation. Notably, loss of CCN1 also disrupted the development of vascular networks in the ectopic lesions and reduced the expression of several angiogenic factors, such as vascular endothelial growth factor-A and vascular endothelial growth factor-C. These results suggest that CCN1, acting downstream of E, critically controls cell proliferation and neovascularization, which support the growth and survival of endometriotic tissue at ectopic sites. Blockade of CCN1 signaling during the early stages of lesion establishment may provide a therapeutic avenue to control endometriosis.

Download Full-text